Zanubrutinib
![Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA](https://pharmtales.com/wp-content/uploads/2023/07/Zanubrutinib-Plus-Obinutuzumab-for-R_R-Follicular-Lymphoma-Receives-FDA-Acceptance-of-sNDA.jpg)
Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA
SG Tylor
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...